Susquehanna International Group
TERN

Susquehanna International Group’s Terns Pharmaceuticals TERN Stock Holding History

Susquehanna International Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.6M Buy
1,016,400
+546,800
+116% +$22.5M 0.01% 1240
2025
Q4 		$19M Buy
469,600
+299,300
+176% +$6.92M ﹤0.01% 2271
2025
Q3 		$1.28M Buy
170,300
+157,900
+1,273% +$1.01M ﹤0.01% 6746
2025
Q2 		$46.3K Sell
12,400
-113,300
-90% -$354K ﹤0.01% 12136
2025
Q1 		$347K Sell
125,700
-124,200
-50% -$507K ﹤0.01% 9736
2024
Q4 		$1.38M Buy
249,900
+800
+0.3% +$5.42K ﹤0.01% 6146
2024
Q3 		$2.08M Sell
249,100
-9,800
-4% -$80.6K ﹤0.01% 5198
2024
Q2 		$1.76M Buy
258,900
+157,500
+155% +$954K ﹤0.01% 5340
2024
Q1 		$665K Buy
101,400
+56,300
+125% +$368K ﹤0.01% 7816
2023
Q4 		$293K Buy
45,100
+13,400
+42% +$70.8K ﹤0.01% 9897
2023
Q3 		$159K Buy
31,700
+16,400
+107% +$104K ﹤0.01% 10483
2023
Q2 		$134K Buy
+15,300
New +$178K ﹤0.01% 10686

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Susquehanna International Group's TERN Position: Q1 2026 in Review

Susquehanna International Group increased its Terns Pharmaceuticals (TERN) stake by 6,765% in Q1 2026, buying an estimated $21.1M and bringing the position to 521,571 shares worth $27.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1844.

Susquehanna International Group first reported a position in TERN in Q4 2022 and has held it in 13 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Susquehanna International Group held 521,571 shares of Terns Pharmaceuticals worth $27.5M as of Q1 2026.
  • Susquehanna International Group bought 513,974 Terns Pharmaceuticals shares in Q1 2026, an estimated $21.1M.
  • Terns Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1844 holding.
  • Susquehanna International Group first reported a position in Terns Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.